Comparison of Fluconazole Versus Voriconazole to Treat Fungal Infections in Individuals Receiving Blood and Marrow Transplants (BMT CTN 0101)

This study has been completed.
Sponsor:
Collaborators:
Blood and Marrow Transplant Clinical Trials Network
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00075803
First received: January 9, 2004
Last updated: November 20, 2009
Last verified: November 2009
  Purpose

The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.


Condition Intervention Phase
Lymphoma
Infection
Leukemia
Drug: Fluconazole
Drug: Voriconazole
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Double-blind Trial of Fluconazole Versus Voriconazole for the Prevention of Invasive Fungal Infections in Allogeneic Blood and Marrow Transplant Patients (BMT CTN #0101)

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Primary Outcome Measures:
  • Fungal-free survival (proportion of participants alive and free from proven, probable, or presumptive invasive fungal infection) at 180 days post-transplant [ Time Frame: 180 days ]

Secondary Outcome Measures:
  • Frequency of invasive fungal infections [ Time Frame: 1 year ]
  • Time to invasive fungal infection [ Time Frame: 1 year ]
  • survival [ Time Frame: 1 year ]
  • Frequency and duration of use of amphotericin B or caspofungin [ Time Frame: 1 year ]
  • Time to and severity of acute and chronic GVHD [ Time Frame: 1 year ]
  • Utility of galactomannan assay in diagnosis of aspergillus and response to therapy [ Time Frame: 1 year ]
  • Time to neutrophil engraftment [ Time Frame: 28 days ]
  • Time to platelet engraftment [ Time Frame: 180 days ]
  • Freedom from possible, presumptive, probable, or proven invasive fungal infection, death, or withdrawal of study drug due to toxicity, intolerance, or an empirical trial of amphotericin B or caspofungin greater than 14 consecutive days [ Time Frame: 1 year ]

Enrollment: 600
Study Start Date: November 2003
Study Completion Date: September 2007
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
fluconazole
Drug: Fluconazole
Age Drug Route Renal Function Dosage Adult fluconazole PO normal 400 mg/d voriconazole PO normal 200 mgQ12H Adult * fluconazole PO < 50 mg/min 200 mg/d voriconazole PO < 50 mg/min 200 mgQ12H Age < 12 and > 20 kg fluconazole PO normal 200 mg/d voriconazole PO normal 100 mgQ12H Age < 12 and > 20 kg * fluconazole PO < 50 mg/min 100 mg/d voriconazole PO < 50 mg/min 100 mgQ12H Age < 12 and < 20 kg fluconazole PO normal 100 mg/d voriconazole PO normal 50 mgQ12H
Experimental: 2
voriconazole
Drug: Voriconazole
Age Drug Route Renal Function Dosage Adult fluconazole PO normal 400 mg/d voriconazole PO normal 200 mgQ12H Adult * fluconazole PO < 50 mg/min 200 mg/d voriconazole PO < 50 mg/min 200 mgQ12H Age < 12 and > 20 kg fluconazole PO normal 200 mg/d voriconazole PO normal 100 mgQ12H Age < 12 and > 20 kg * fluconazole PO < 50 mg/min 100 mg/d voriconazole PO < 50 mg/min 100 mgQ12H Age < 12 and < 20 kg fluconazole PO normal 100 mg/d voriconazole PO normal 50 mgQ12H

Detailed Description:

BACKGROUND:

Allogeneic blood and marrow transplant patients are highly susceptible to invasive fungal infection prior to engraftment, due to neutropenia and mucosal injury. After engraftment, an impairment of cell mediated immunity from graft-versus-host disease (GVHD) and the use of aggressive immunosuppressive therapies, such as corticosteroids, leave patients vulnerable to invasive fungal infections. Recipients of alternate donor transplants are especially susceptible due to slow reconstitution of cell mediated immunity.

Fluconazole prophylaxis in prospective randomized trials of both autologous and allogeneic transplant recipients has been demonstrated to reduce invasive fungal infections due to yeasts prior to engraftment. A prolonged course of fluconazole given during the first 75 days (to cover the early post-engraftment period of risk) is highly effective in the prevention of early and later yeast infections. This has translated into a survival benefit. A recent analysis of long-term outcomes of these individuals demonstrated a continuing benefit beyond the course of prophylaxis with a further benefit in survival. In another study of various factors associated with survival after matched unrelated donor transplants, fluconazole prophylaxis was an independent predictor for overall survival in a multivariate analysis. Fluconazole prophylaxis has been found to be effective and safe with few substantive drug interactions and has been widely adopted by transplant clinicians.

DESIGN NARRATIVE:

This is a randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic hematopoietic transplant recipients and cord blood recipients in children under the age of 12. Prior to the start of the pre-transplant conditioning regimen, participants will give written informed consent and be screened for eligibility. Participants who meet all entry criteria will be assigned randomly to voriconazole or fluconazole within 72 hours of Day 0. Participants will begin the study drug on Day 0 (after completion of the conditioning regimen). Day 0 is defined as the day infusion of the stem cell product is completed. The study drug will be continued until Day 100 following transplant or until one or more criteria for early withdrawal are met. Continuation of the study drug beyond Day 100 is permitted for participants who meet specific criteria. The development of any fungal infection during prophylaxis will be classified according to the definitions listed in the protocol.

  Eligibility

Ages Eligible for Study:   2 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must receive an allogeneic peripheral blood or marrow transplant from a family or unrelated donor, or for children under the age of 12, a cord blood transplant from either a sibling or other donor
  • Must have a 5 or 6 of 6 human leukocyte antigens (HLA)-matched donor. The match may be determined at serologic level for HLA-A and HLA-B loci. For sibling donors, matching may be determined at serologic level for HLA-DR; for unrelated donors, matching for HLA-DRB1 must be at the high-resolution molecular level
  • Must have one of the following underlying diseases:

    1. Acute myelogenous leukemia (AML)
    2. Acute lymphocytic leukemia (ALL)
    3. Acute undifferentiated leukemia (AUL)
    4. Acute biphenotypic leukemia in first or second complete remission
    5. Chronic myelogenous leukemia (CML) in either chronic or accelerated phase
    6. One of the following myelodysplastic syndrome(s) (MDS):

      1. Refractory anemia
      2. Refractory anemia with ringed sideroblasts
      3. Refractory cytopenia with multilineage dysplasia
      4. Refractory cytopenia with multilineage dysplasia and ringed sideroblasts
      5. Refractory anemia with excess blasts-1 (5-10% blasts)
      6. Refractory anemia with excess blasts-2 (10-20% blasts)
      7. MDS, unclassified
      8. MDS associated with isolated del (5q)
      9. Chronic myelomonocytic leukemia (CMML)
    7. Lymphoma (including Hodgkin's) with chemosensitive disease (at least 50% response to chemotherapy) and receiving a related donor transplant
  • Receiving myeloablative conditioning regimens
  • Adequate physical function (cardiac, hepatic, renal, and pulmonary), within 6 weeks of initiation of conditioning (preferably within 4 weeks) unless otherwise specified
  • Baseline galactomannan blood samples drawn within 30 days prior to randomization with the results available prior to randomization (72 hours prior to transplant)
  • Chest computed tomography (CT) scans within 6 weeks prior to randomization if the results of the baseline galactomannan blood sample are not available prior to randomization (72 hours prior to transplant)

Exclusion Criteria:

  • Invasive yeast infection within the 8 weeks prior to conditioning regimen initiation. Patients are eligible if colonized or have had superficial infection. Patients with a history of candidemia greater than 8 weeks prior to conditioning must have a negative blood culture within 14 days of conditioning (within 7 days is recommended), no clinical signs of candidemia, and may not still require antifungal therapy
  • Presumptive, proven, or probable aspergillus or other mold infection or deep mycoses (including hepatosplenic candidiasis) within 4 months prior to conditioning regimen initiation
  • Uncontrolled viral or bacterial infection at the time of study registration
  • Pregnant or breastfeeding. Women of child-bearing age must avoid becoming pregnant while receiving antifungal agents
  • Karnofsky performance status less than 70% or Lansky status less than 50% for patients under 16 years old unless approved by the medical monitor or protocol chair
  • History of allergy or intolerance to azoles (e.g., fluconazole, itraconazole, voriconazole, posaconazole, ketoconazole, miconazole, clotrimazole)
  • Requiring therapy with rifampin, rifabutin, carbamazepine, cisapride (Propulsid®), terfenadine (Seldane®), astemizole (Hismanal®), ergot alkaloids, long-acting barbiturates, or who have received more than 3 days treatment with rifampin or carbamazepine within 7 days prior to conditioning regimen initiation. Patients on therapeutic anticoagulation with coumadin (1 mg/day for port prophylaxis is permitted)
  • Receiving sirolimus
  • Prolonged QTc syndrome at study entry
  • HIV positive
  • Receiving another investigational drug unless cleared by the medical monitors
  • Received a prior allogeneic or autologous transplant
  • Active central nervous system disease
  • On fungal prophylaxis during conditioning regimen (it is recommended that fungal prophylaxis be suspended once patient is enrolled)
  • Prior cancer, other than resected basal cell carcinoma or treated carcinoma in-situ. Cancer treated with curative intent less than 5 years previously will not be allowed unless approved by the medical monitor or protocol chair. Cancer previously treated with curative intent over 5 years ago will be allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00075803

  Show 34 Study Locations
Sponsors and Collaborators
Blood and Marrow Transplant Clinical Trials Network
Investigators
Principal Investigator: Donna Salzman, MD University of Alabama at Birmingham
Principal Investigator: Jeffrey Andrey, MD Scripps Cancer Center
Principal Investigator: Janice Brown, MD Stanford Hospital and Clinics
Principal Investigator: Edward Ball, MD UCSD Medical Center
Principal Investigator: Naynesh Kamani, MD Children's Research Institute
Principal Investigator: Claudio Anasetti, MD H. Lee Moffitt Cancer Center
Study Chair: John Wingard, MD University of Florida College of Medicine (Shands)
Principal Investigator: Reggie Duerst, MD Children's Memorial - Northwestern
Principal Investigator: Paul Haut, MD Indiana University School of Medicine
Principal Investigator: Lindsey Robert Baden, MD Dana Farber Cancer Institute/Brigham & Womens
Principal Investigator: Leslie Lehmann, MD Dana Farber Cancer Institute/Children's Hospital of Boston
Principal Investigator: Richard Jones, MD Johns Hopkins/SKCCC
Principal Investigator: Voravit Ratanatharathorn, MD Karmanos Cancer Institute/BMT
Principal Investigator: Choon-Kee Lee, MD University of Michigan
Principal Investigator: Jo-Anne van Burik, MD University of Minnesota - Clinical and Translational Science Institute
Principal Investigator: William Ferguson, MD Cardinal Glennon Children's Hospital
Principal Investigator: Alan Gamis, MD Children's Mercy Hospital Kansas City
Principal Investigator: Joseph McGuirk, MD Kansas City Cancer Centers
Principal Investigator: John DiPersio, MD Washington University/Barnes Jewish Hospital
Principal Investigator: Shalini Shenoy, MD Washington University/St. Louis Children's Hospital
Principal Investigator: Joanne Kurtzberg, MD Duke University
Principal Investigator: Kevin High, MD Wake Forest School of Medicine
Principal Investigator: Marcel Devetten, MD University of Nebraska
Principal Investigator: Scott Rowley, MD Hackensack University Medical Center
Principal Investigator: Joel Brochstein, MD Hackensack University Medical Center
Principal Investigator: Trudy Small, MD Memorial Sloan-Kettering Cancer Center
Principal Investigator: Brahm Segal, MD Roswell Park Cancer Institute
Principal Investigator: Hillard Lazarus, MD University Hospitals of Cleveland/Case Western
Principal Investigator: Richard Maziarz, MD Oregon Health and Science University
Principal Investigator: H. Stacy Nicholson, MD Oregon Health and Science University
Principal Investigator: Nancy Bunin, MD Children's Hospital of Philadelphia
Principal Investigator: Edward Stadtmauer, MD University of Pennsylvania
Principal Investigator: Paul Shaughnessy, MD Texas Transplant Institute
Principal Investigator: Michael Grimley, MD Texas Transplant Institute
Principal Investigator: Sergio Giralt, MD University of Texas/MD Anderson CRC
Principal Investigator: Michael Pulsipher, MD Utah BMT/Primary Children's Medical Center
Principal Investigator: Kieren Marr, MD Fred Hutchinson Cancer Research Center
  More Information

No publications provided by National Heart, Lung, and Blood Institute (NHLBI)

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Shelly Carter, ScD, The EMMES Corporation
ClinicalTrials.gov Identifier: NCT00075803     History of Changes
Obsolete Identifiers: NCT00322088
Other Study ID Numbers: 416, BMTCTN-0101, UF-G-074-2003, FHCRC-1808.00, CDR0000349374, U01 HL069294
Study First Received: January 9, 2004
Last Updated: November 20, 2009
Health Authority: United States: Federal Government
United States: Food and Drug Administration

Keywords provided by National Heart, Lung, and Blood Institute (NHLBI):
Myelodysplastic and Myeloproliferative Diseases

Additional relevant MeSH terms:
Leukemia
Lymphoma
Mycoses
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Fluconazole
Voriconazole
Antifungal Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
14-alpha Demethylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 01, 2014